PRAME EXPRESSION IN CANCER. A SYSTEMATIC IMMUNOHISTOCHEMICAL STUDY OF >5800 EPITHELIAL AND NONEPITHELIAL TUMORS.

By M. Kaczorowski, Małgorzata Chłopek, A. Kruczak, J. Ryš, J. Lasota, M. Miettinen. 2022

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “PRAME has emerged as a pan-cancer target, supported by systematic reviews [14] and on-going clinical trials investigating autologous T cell therapies in PRAME-positive advanced solid tumors [24].”